Brii Biosciences>   Susannah Cantrell, PhD
Susannah Cantrell, PhD

Susannah Cantrell, PhD

Susannah Cantrell, PhD is a highly experienced professional with 32.8 years of work experience in the pharmaceutical industry. She has a strong background in oncology, biotechnology, and pharmaceutical sales. Currently, she serves as the Sr. Director of Worldwide Commercial Operations at Gilead Sciences. Throughout her career, she has held various leadership positions in renowned companies such as Brii Biosciences and Second Genome Inc. Susannah's expertise lies in product launch, cross-functional team leadership, and strategy. She is based in San Francisco, California. .Read More

Susannah Cantrell, PhD Contact information

Add to List
Sequence
Dialer

Susannah Cantrell, PhD Current Workspace

Angela Work Summary

Number of Companies worked For
20
Average duration at company ( Year )
2
Number of job Positions
18

About Susannah Cantrell, PhD

Sr. Director, Worldwide Commercial Operations at Gilead Sciences .Read More

Susannah Cantrell, PhD’s Activities

We are hiring! I'm looking for an experienced leader to join BriiBio to lead our Portfolio Strategy & Management. Please see job posting on our careers page: https://lnkd.in/gAvfDqvZ .Read More
November 05 2022
Show all activites

Susannah Cantrell, PhD's Current Workspace

Brii Biosciences
Brii Biosciences2022-07-01 - Present
Brii Biosciences is a biotechnology company developing therapies to address some of the world’s most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK. .Read More

Susannah Cantrell, PhD's Work